Duyuru • 18h
Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd. On August 17, 2026, Neurothera Labs Inc. has closed the transaction by closing its final tranche. The company issued 22,500,000 units at CAD 0.12 per Unit for gross proceeds of CAD 2,700,000 under its final tranche. Each Unit Warrant entitles the holder to purchase one Common Share at an exercise price of $0.115 per Common Share, equivalent to CAD 0.16 per Common Share, until August 17, 2029. All securities issued in connection with the Final Tranche, including the Common Shares and the Unit Warrants, and any Common Shares issuable upon exercise of the Unit Warrants, are subject to a holding period of four months and one day from August 17, 2026. The Offering is subject to the final approval of the TSX Venture Exchange and any other applicable regulatory approvals. SciSparc Ltd., a control person of the Company, participated in the Offering by subscribing for 22,500,000 Units for an aggregate subscription price of CAD 2,700,000. SciSparc’s Ltd.’s participation in the Offering constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Duyuru • Aug 13
Neurothera Labs Granted Japanese Patent for Proprietary Therapeutic Combination NeuroThera Labs Inc. announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever, and related conditions. The addition of Japanese patent coverage marks an important strategic milestone as NeuroThera advances its next-generation therapeutic innovations across global markets. NeuroThera continues to advance its therapeutic platforms with the goal of delivering safe, effective, and accessible treatments to patients worldwide. Duyuru • Aug 05
NeuroThera Labs Initiates Phase IIb Clinical Trial For SCI-110 At Yale Child Study Center NeuroThera Labs Inc. announced the initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome in adults. The trial is now progressing at the Yale Child Study Center, one of the study’s key clinical sites. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single, innovative dosage form designed to reduce tics and associated comorbid symptoms in adults with Tourette Syndrome while aiming to minimize side effects. In addition to the Yale site, the Phase IIb trial is also underway at Hannover Medical School in Hanover, Germany, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events. Duyuru • Jul 31
Neurothera Labs Demonstrates End-To-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics NeuroThera Labs announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics. The Platform has successfully demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework, from secure data ingestion and preparation, through quantum-enabled analytical processing, to the generation of biologically and clinically interpretable insights. The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes relevant to the Platform's analytical architecture. The Platform's proprietary analytical framework is designed to enable quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical datasets. This milestone confirms that the Platform can support a complete hybrid quantum-classical analytical workflow designed to address complex, high-dimensional biomedical datasets while applying quantum-inspired and quantum-enabled methodologies to uncover non-obvious patterns, all while maintaining alignment with downstream scientific interpretation requirements. The Platform is being advanced through CliniQuantum Ltd., a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%. Duyuru • Jul 29
NeuroThera Labs Inc Advances Quantum Platform for Clinical Data Analytics on A Platform of an S&P 500 Company NeuroThera Labs Inc. has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis. The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum-classical computing. The validation supports a key component of the Platform's computational architecture and is expected to further expand the Platform’s capabilities for addressing complex analytical challenges involving large-scale clinical and biomedical datasets. Many real-world challenges in healthcare, life sciences, drug development and advanced analytics are naturally represented as continuous probability distributions. The Platform’s proprietary methodology converts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov Chain Monte Carlo techniques while preserving the statistical characteristics of the original data. By using the Platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous datasets to be explored through quantum-generated proposals while maintaining established statistical guarantees. The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. The Platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%. Duyuru • Jul 16
Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome NeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events. Duyuru • Jul 02
Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding NeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at an issue price of CAD 0.135 for gross proceeds of CAD 5,001,750 on June 30, 2026. Each Unit will be comprised of one common share in the capital of the Company and one transferable common share purchase warrant entitling the holder thereof to acquire one common share in the capital of the Company at a price of CAD 0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof. Certain insiders of the Company may acquire Offered Units in the Offering. The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such Offered Units. The Company may pay finder's fees on a portion of the Offering, subject to applicable securities legislation. Closing of the Offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the Offering. Any participation by insiders of the Company in the Offering will be on the same terms as arm’s length investors. Duyuru • Jun 04
Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. Neurothera Labs Inc. (TSXV:NTLX) entered into a definitive share purchase agreement to acquire 54.01% stake in CliniQuantum Ltd. for $9 million on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. The Approval of the Neurothera Labs's Board of Directors and Shareholders has been received
Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. As of May 27, 2026, the outside date for the completion of the transaction has been extended to June 1, 2026. On May 28, 2026, parties received a conditional regulatory approval from the TSX Venture Exchange.
I.F.S. Consulting and Investments (2009) Ltd acted as fairness opinion provider for Neurothera Labs Inc.
Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. on June 3, 2026.
Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., is also a director of Quantum X Labs Ltd., which holds the remaining approximately 45.98% of the ordinary shares of CliniQuantum.
Closing of the Transaction has occurred following receipt of all necessary corporate approvals and final acceptance of the TSXV. Duyuru • Mar 17
Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy SciSparc Ltd. reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025. Duyuru • Mar 11
CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction. CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction.
Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. New Risk • Mar 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (462% increase in shares outstanding). Market cap is less than US$10m (CA$13.2m market cap, or US$9.65m). Duyuru • Jan 27
Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd. Neurothera Labs Inc. (TSXV:NTLX) entered into a binding term sheet to acquire Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd on November 26, 2025. On January 8, 2026, SciSparc Ltd. (NasdaqCM:SPRC) entered into a definitive agreement to acquire Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd. The consideration consists of issue to Xylo an amount of ordinary shares of the SciSparc, which shall represent as of the closing date, 19.99% of the issued and outstanding share capital of the SciSparc. As part of consideration, an undisclosed value is paid towards assets of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd. The closing of the transaction will be subject to customary closing conditions, including receipt of shareholder approval, required regulatory approvals, negotiating and signing definitive agreements for the acquisition and is expected to close on March 8, 2026.
Meytal Katz of Primes & Co. acted as legal advisor for Xylo Technologies. Shachar Hadar of Meitar acted as legal advisor for SciSparc Ltd.
Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd on January 26, 2026. Duyuru • Jan 01
NeuroThera Labs Inc. Grants Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects SciSparc Ltd. announced that NeuroThera Labs Inc. announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues. This patent grant in Israel joins previously granted patents for the same technology in Europe, Japan, Australia, and Canada, further strengthening the global intellectual property protection of Neurothera's proprietary opioid-based platform. The patented technology leverages N-acylethanolamine, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms that amplify pain-relieving efficacy at lower doses. This patent family is based on a pre-clinical study conducted to evaluate the nociceptive effect of PEA when combined with opioids such as oxycodone, in well-established, regulatory compliance, pre-clinical models. In this study, researchers evaluated the pain relief potential of Neurothera's proprietary drug combination of oxycodone and PEA versus standalone oxycodone in numerous concentrations. Results showed that while oxycodone treatment led to marked alteration in animals' behavior and their response to pain stimuli, Neurothera''s proprietary combination was found to exert beneficial effects like reduction or even preventing some of oxycodone drugs psychoactive adverse events. The "opioid-sparing" effect shown in this study by Neurothera''s proprietary collaboration may reduce the required opioid dosage, which may help mitigate side effects such as addiction and respiratory depression. Duyuru • Nov 11
Neurothera Labs Inc., Annual General Meeting, Jan 08, 2026 Neurothera Labs Inc., Annual General Meeting, Jan 08, 2026. 
